S&P 500   3,750.77
DOW   30,303.17
QQQ   319.43
S&P 500   3,750.77
DOW   30,303.17
QQQ   319.43
S&P 500   3,750.77
DOW   30,303.17
QQQ   319.43
S&P 500   3,750.77
DOW   30,303.17
QQQ   319.43
Log in

Smith & Nephew Stock Forecast, Price & News

-1.91 (-4.19 %)
(As of 01/27/2021 12:00 AM ET)
Today's Range
Now: $43.67
50-Day Range
MA: $42.77
52-Week Range
Now: $43.67
Volume479,806 shs
Average Volume386,206 shs
Market Capitalization$19.15 billion
P/E Ratio21.41
Dividend Yield1.23%
Smith & Nephew plc develops, manufactures, and sells medical devices worldwide. The company offers knee implant products for specialized knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
Smith & Nephew logo


Overall MarketRank

1.77 out of 5 stars

Medical Sector

149th out of 1,926 stocks

Surgical Appliances & Supplies Industry

6th out of 40 stocks

Analyst Opinion: 2.2Community Rank: 1.9Dividend Strength: 1.7Insider Behavior: 0.0Valuation: 3.1 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Surgical appliances & supplies
Year FoundedN/A



Sales & Book Value

Annual Sales$5.14 billion
Cash Flow$3.22 per share
Book Value$11.76 per share



Market Cap$19.15 billion
Next Earnings Date2/18/2021 (Estimated)
-1.91 (-4.19 %)
(As of 01/27/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SNN News and Ratings via Email

Sign-up to receive the latest news and ratings for SNN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Smith & Nephew (NYSE:SNN) Frequently Asked Questions

How has Smith & Nephew's stock price been impacted by Coronavirus (COVID-19)?

Smith & Nephew's stock was trading at $38.73 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, SNN shares have increased by 12.8% and is now trading at $43.67.
View which stocks have been most impacted by COVID-19

Is Smith & Nephew a buy right now?

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Smith & Nephew in the last twelve months. There are currently 2 sell ratings, 3 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Smith & Nephew stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SNN, but not buy additional shares or sell existing shares.
View analyst ratings for Smith & Nephew
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Smith & Nephew?

Wall Street analysts have given Smith & Nephew a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Smith & Nephew wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Smith & Nephew's next earnings date?

Smith & Nephew is scheduled to release its next quarterly earnings announcement on Thursday, February 18th 2021.
View our earnings forecast for Smith & Nephew

How were Smith & Nephew's earnings last quarter?

Smith & Nephew plc (NYSE:SNN) posted its quarterly earnings results on Monday, November, 17th. The medical equipment provider reported $0.98 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.39 by $0.59.
View Smith & Nephew's earnings history

How often does Smith & Nephew pay dividends? What is the dividend yield for Smith & Nephew?

Smith & Nephew declared a Semi-Annual dividend on Wednesday, July 29th. Shareholders of record on Friday, October 2nd will be paid a dividend of $0.278 per share on Wednesday, October 28th. This represents a dividend yield of 1.8%. The ex-dividend date of this dividend is Thursday, October 1st.
View Smith & Nephew's dividend history

Is Smith & Nephew a good dividend stock?

Smith & Nephew pays an annual dividend of $0.56 per share and currently has a dividend yield of 1.23%. The dividend payout ratio of Smith & Nephew is 27.45%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Smith & Nephew will have a dividend payout ratio of 29.02% next year. This indicates that Smith & Nephew will be able to sustain or increase its dividend.
View Smith & Nephew's dividend history.

What price target have analysts set for SNN?

11 equities research analysts have issued 1 year target prices for Smith & Nephew's stock. Their forecasts range from $42.00 to $48.00. On average, they anticipate Smith & Nephew's share price to reach $45.50 in the next twelve months. This suggests a possible upside of 4.2% from the stock's current price.
View analysts' price targets for Smith & Nephew
or view Wall Street analyst' top-rated stocks.

Who are some of Smith & Nephew's key competitors?

What other stocks do shareholders of Smith & Nephew own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Smith & Nephew investors own include Smith & Nephew plc (SN.L) (SN), RPM International (RPM), Gilead Sciences (GILD), AbbVie (ABBV), Alibaba Group (BABA), Johnson & Johnson (JNJ), Pfizer (PFE), Abbott Laboratories (ABT), Alexion Pharmaceuticals (ALXN) and Amgen (AMGN).

Who are Smith & Nephew's key executives?

Smith & Nephew's management team includes the following people:
  • Mr. Roland D. Diggelmann, Chief Exec. Officer (Age 54, Pay $1.49M)
  • Ms. Anne-Francoise Nesmes, CFO & Exec. Director (Age 50)
  • Mr. Mark Gladwell, Pres of Global Operations and Global Bus. Services (Age 46)
  • Mr. Andrew Swift, VP of Investor Relations
  • Ms. Catheryn O'Rourke, Chief Legal & Compliance Officer (Age 48)
  • Mr. Joe Metzger, Sr. VP of Marketing Services & Communications
  • Ms. Elga Lohler, Chief HR Officer (Age 53)
  • Mr. Philip G. Cowdy, Chief Bus. Devel. & Corp. Affairs Officer (Age 54)
  • Mr. Bradley Cannon, Pres of Sports Medicine & ENT (Age 53)
  • Dr. Vasant Padmanabhan, Pres of R&D (Age 54)

What is Smith & Nephew's stock symbol?

Smith & Nephew trades on the New York Stock Exchange (NYSE) under the ticker symbol "SNN."

Who are Smith & Nephew's major shareholders?

Smith & Nephew's stock is owned by a variety of retail and institutional investors. Top institutional investors include Boston Trust Walden Corp (0.02%), Crossmark Global Holdings Inc. (0.01%), Manning & Napier Group LLC (0.01%), Janney Montgomery Scott LLC (0.01%), Highland Capital Management LLC (0.01%) and Raymond James Trust N.A. (0.00%).

Which major investors are selling Smith & Nephew stock?

SNN stock was sold by a variety of institutional investors in the last quarter, including Crossmark Global Holdings Inc., Park Avenue Securities LLC, Private Capital Group LLC, Pacer Advisors Inc., Manning & Napier Group LLC, Janney Montgomery Scott LLC, and Park National Corp OH.

Which major investors are buying Smith & Nephew stock?

SNN stock was purchased by a variety of institutional investors in the last quarter, including Leavell Investment Management Inc., Raymond James Trust N.A., Sowell Financial Services LLC, Rowland Carmichael Advisors Inc. ADV, Highland Capital Management LLC, International Assets Investment Management LLC, Simon Quick Advisors LLC, and Boston Trust Walden Corp.

How do I buy shares of Smith & Nephew?

Shares of SNN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Smith & Nephew's stock price today?

One share of SNN stock can currently be purchased for approximately $43.67.

How big of a company is Smith & Nephew?

Smith & Nephew has a market capitalization of $19.15 billion and generates $5.14 billion in revenue each year. The medical equipment provider earns $600 million in net income (profit) each year or $2.04 on an earnings per share basis. Smith & Nephew employs 17,637 workers across the globe.

What is Smith & Nephew's official website?

The official website for Smith & Nephew is www.smith-nephew.com.

How can I contact Smith & Nephew?

Smith & Nephew's mailing address is BUILDING 5 CROXLEY PARK HATTERS LANE, WATFORD X0, WD18 8YE. The medical equipment provider can be reached via phone at 44-19-2347-7100 or via email at [email protected]

This page was last updated on 1/28/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.